enVVeno Medical (NASDAQ:NVNO) Participates in Virtual Investor "What This Means" Segment
-
Trump to promise 'turnaround for the ages' in State of the Union
-
Economy not Russia is big fear on Finland's closed frontier
-
Alexandria bids farewell to historic tram in latest urban upheaval
-
The veteran 'insider' shaping Iran's nuclear policy
-
'Jaws' harpoon gun and 'Star Wars' treasures lead LA film and TV auction
-
Brazil prosecutor urges politicians' conviction in murder of black councilwoman
-
Starved of fuel, Cubans scramble to make ends meet
-
Giant killers Bodo/Glimt continue remarkable rise with Inter triumph
-
Bodo/Glimt knock Inter out of Champions League as Newcastle, Atletico reach last 16
-
Australian Open chief Tiley steps down to take top US job
-
Crime capital no more: El Salvador tourism boosted by Bukele
-
FIFA boss 'very reassured' about World Cup in Mexico despite violence
-
15 states sue Trump administration over child vaccine policy
-
Rescuers search for missing after deluge kills 30 in Brazil
-
Newcastle complete cruise into Champions League last 16
-
Leverkusen through to Champions League last 16 after Olympiacos draw
-
Bodo/Glimt sink Inter to continue Champions League fairy tale
-
Tech shares rebound as markets weigh AI impacts
-
Puerto Vallarta: the Mexican paradise in flames over the killing of 'El Mencho'
-
Sorloth treble helps Atletico past Brugge into Champions League last 16
-
Louvre president hands in resignation to Macron: Elysee
-
Iran says deal 'within reach' ahead of US talks
-
Torrential rains leave 25 dead in Brazil, dozens missing
-
Northeast US faces power cuts and school closures after snowstorm
-
US abstains in UN vote voicing support for Ukraine
-
Lebanon fears Israeli strikes if Iran situation escalates
-
Trump seeks to strike back in crucial State of the Union
-
World-class Brook played 'the best innings of his life' - Afridi
-
US appeals WTO ruling in dispute by China over clean energy subsidies
-
Guadalajara: World Cup host city rocked by narco violence
-
Briiliant Brook 100 puts England into T20 World Cup semi-finals
-
Germany's Merz heads to China for talks centred on trade
-
Briiliant Brook 100 puts England into T20 World Cups semi-finals
-
Warner Bros. 'reviewing' new takeover bid from Paramount
-
US told EU it 'stands' by tariff deal: trade chief
-
Torrential rains leave 23 dead in Brazil, dozens missing
-
UK govt says will release files on 'rude' ex-prince Andrew
-
Nearly an own gull! CPR performed on bird at Turkey football match
-
How AFP has used data analysis to cover the Ukraine war
-
Paris says US envoy pledges not to 'interfere' in France affairs
-
Iran says students must respect 'red lines' after protests
-
Italian biathlete Giacomel has heart surgery after Olympic withdrawal
-
Gazans salvage ancient books in mosque library damaged by war
-
Farhan scores 63 as England restrict Pakistan to 164-9
-
Stocks bounce as traders assess AI fallout, tariffs
-
Brazil court tries politicians over hit on Black councilwoman
-
Senegal PM vows to double penalty for same-sex relations
-
UK govt backs releasing documents tied to 'rude' ex-prince Andrew
-
Novo Nordisk to slash prices of weightloss drugs in US
-
Welllage says Sri Lanka can rescue T20 World Cup campaign
enVVeno Medical (NASDAQ:NVNO) Participates in Virtual Investor "What This Means" Segment
Watch the "What This Means" video here
IRVINE, CA / ACCESS Newswire / September 26, 2025 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of deep venous disease, today announced that Robert Berman, Chief Executive Officer of enVVeno Medical participated in a Virtual Investor "What This Means" segment.
As part of the segment, Mr. Berman discussed the Company's recent news announcing it filed a request for supervisory appeal of the not-approvable letter from the Center for Devices and Radiological Health (CDRH) of the U.S. Food & Drug Administration (FDA) received on August 19, 2025, in response to its Premarket Approval (PMA) application for the VenoValve®, a surgical replacement venous valve for treating severe deep chronic venous insufficiency (CVI).
The Virtual Investor "What This Means" segment featuring enVVeno Medical is now available here.
About enVVeno Medical Corporation
enVVeno Medical (NASDAQ:NVNO) is an Irvine, California-based, late clinical-stage medical device Company focused on the advancement of innovative bioprosthetic (tissue-based) solutions to improve the standard of care for the treatment of deep venous disease. The Company's lead product, the VenoValve®, is a first-in-class surgical replacement venous valve being developed for the treatment of severe deep Chronic Venous Insufficiency (CVI). The Company is also developing a non-surgical, transcatheter based replacement venous valve for the treatment of deep venous CVI called enVVe®. Both the VenoValve and enVVe are designed to act as one-way valves, to help assist in propelling blood up the leg, and back to the heart and lungs. The Company is currently performing the final testing necessary to seek IDE approval from the FDA to begin the U.S. pivotal trial for enVVe.
INVESTOR CONTACT:
Jenene Thomas, JTC Team, LLC
[email protected]
(908) 824-0775
MEDIA CONTACT:
Glenn Silver, FINN Partners
[email protected]
(973) 818-8198
SOURCE: enVVeno Medical Corporation
View the original press release on ACCESS Newswire
Y.Nakamura--AMWN
